Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.61 |
| ▸ | MMP9 | P14780 | 6/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7694788 | 0.95 | MMP2 (0.56) | MMP2MMP9ITGB3ITGA2BCA2 | |
| SCHEMBL7420817 | 0.93 | ITGB3 (0.56) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7415221 | 0.92 | ITGB3 (0.53) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7411712 | 0.92 | TDP1 (0.59) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7409585 | 0.91 | ITGB3 (0.61) | MMP2MMP9ITGB3ITGA2BADAMTS4 | |
| SCHEMBL7693853 | 0.91 | ITGB3 (0.51) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7414982 | 0.90 | ITGB3 (0.52) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7410503 | 0.90 | ITGB3 (0.52) | MMP2MMP9ITGB3ITGA2BTDP1 | |
| SCHEMBL7412146 | 0.90 | MMP2 (0.56) | MMP2MMP9ITGB3ITGA2BADAMTS4 | |
| SCHEMBL7417646 | 0.90 | MMP2 (0.56) | MMP2MMP9ITGB3ITGA2BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | claimed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |